Overview: Where Simulation Fits
The precision oncology market is well-served for two questions: "What does the patient have?" (diagnostics and profiling) and "What happened historically?" (real-world evidence). DNAI focuses on a different question: "What may happen next under different treatment scenarios?" via physics-constrained simulation.
This is not a replacement for existing tools. It is a complementary layer that takes profiling outputs as input and projects them forward in time under biologically constrained dynamics.
The DNAI Architecture
Multi-modal Encoding
H-BDVAE v5.10
Compress the biology.
Disentangled Latents
328d, biologically structured
Isolate meaningful signals.
Constrained ODEs
Lotka-Volterra dynamics
Model the trajectory.
Landscape: Precision Oncology Data & AI
Leading platforms in this segment focus on large-scale molecular profiling and diagnostic reporting. They provide the critical "what is it?" foundation. DNAI differentiates by adding a temporal dimension: using profiling data as input to constrained dynamical models.
Profiling Platforms
e.g., Tempus, Foundation Medicine, Caris
These platforms excel at large-scale multimodal data aggregation and molecular profiling. They provide risk stratification and treatment matching based on genomic signatures.
Static vs. temporal. Profiling platforms characterize the tumor at a point in time. DNAI takes that characterization as input and projects it forward under constrained population dynamics, ranking treatment scenarios and modeling resistance dynamics.
Predictive AI Platforms
e.g., SOPHiA GENETICS DDM
Newer entrants use machine learning to predict treatment response, typically via patient-similarity matching or statistical outcome models.
Statistical matching vs. constrained dynamics. Patient-similarity approaches rely on finding analogous historical cases. DNAI uses physics-constrained ODEs with hard parameter bounds (proliferation, drug sensitivity, immune interaction), producing trajectories that are guaranteed to satisfy biological constraints by construction.
"Profiling tells you what the tumor is. Simulation explores what it may become."
Landscape: Pathology & Imaging AI
Imaging AI platforms extract quantitative features from histopathology slides and radiology scans. They provide diagnostic support, biomarker quantification, and prognostic scoring. DNAI integrates histopathology embeddings (via UNI2-h) as one input modality alongside omics, using gated fusion to weight imaging evidence against molecular data.
Computational Pathology
e.g., Owkin, PathAI, Paige
These platforms process whole-slide images (WSI) with deep learning for diagnosis, grading, biomarker prediction, and prognostic scoring. Some use federated learning across hospital networks.
Imaging as input, not endpoint. Pathology AI platforms typically output a score or classification. DNAI uses slide-level embeddings as one of several inputs to a Hypernet that parameterizes population dynamics. The histopathology signal contributes to trajectory estimation alongside omics data via learned gated fusion (observed mean: 77% omics / 23% WSI on TCGA validation, Feb 2026; varies by cancer type).
Multimodal Risk Stratification
e.g., ArteraAI
Combines clinical, pathology, and molecular data for risk-level classification (high/intermediate/low).
Risk tiers vs. continuous dynamics. Risk stratification assigns patients to discrete categories. DNAI estimates continuous ODE parameters (growth rate, treatment sensitivity, immune interaction) that produce patient-specific temporal trajectories rather than categorical labels.
"Imaging quantifies the tumor today. Simulation explores how it may respond tomorrow."
Landscape: RWE & Digital Twin Trial Tech
This segment uses historical patient data to construct synthetic control arms, optimize trial designs, and generate real-world evidence. Approaches range from purely statistical to mechanistic simulation. DNAI occupies the intersection: automated, data-driven parameterization of constrained dynamical models.
Statistical Digital Twin Platforms
e.g., Unlearn.AI TwinRCT
Use generative models (variational autoencoders, GANs) to create prognostic digital twins from historical patient data. FDA has accepted these approaches in regulatory submissions.
Statistical generation vs. constrained dynamics. Statistical twins learn the data distribution and generate plausible trajectories. DNAI constrains all outputs to satisfy hard physical bounds (proliferation rate, drug sensitivity, immune interaction coefficients), which prevents non-physical parameter combinations. In our automated validation suite, we observed 0.00% constraint violations (N=9,415; Feb 2026).
Mechanistic QSP Platforms
e.g., Certara Simcyp
Quantitative Systems Pharmacology (QSP) uses mechanistic differential equations with detailed biological compartments. The gold standard for mechanistic rigor in drug development.
Manual parameterization vs. learned parameterization. QSP models require expert-driven parameter selection for each patient or population. DNAI automates this step using a Hypernet that maps multi-omics + histopathology data to ODE parameters, enabling per-patient simulation at scale (~5ms emulator forward pass, excluding WSI feature extraction).
RWE & Data Platforms
e.g., ConcertAI, Flatiron Health
Large-scale real-world data curation and retrospective evidence generation. Essential infrastructure for clinical development and regulatory submissions.
Retrospective evidence vs. counterfactual exploration. RWE platforms analyze what happened in historical cohorts. DNAI uses historical data to parameterize forward-looking simulations, enabling exploration of treatment scenarios that may not exist in the historical record.
"Historical data tells you what happened. Constrained simulation explores what might happen next."
Capabilities Comparison
DNAI Validated Performance (February 2026)
| Capability | Profiling Platforms (Data-first) | Statistical Twins (Generative) | QSP (Mechanistic) | DNAI (Hybrid) |
|---|---|---|---|---|
| Primary Output | Diagnostic report | Probabilistic forecast | Mechanistic simulation | Automated constrained simulation |
| Physical Constraints | None | Statistical only | Manual | Learned + enforced |
| Temporal Modeling | Snapshot | Generated | ODE-based | ODE-based |
| Per-Patient Automation | High | High | Expert-driven | High (~5ms forward pass) |
| Interpretability | Varies | Limited | Full | ODE parameters + attribution |
| Reliability Gating | Rare | Varies | Manual | ISS + OOD + per-cancer |
Note: All DNAI metrics are from research validation studies (Feb 2026). DNAI is for Research Use Only and is not cleared or approved for clinical decision-making. Category descriptions reflect general methodological approaches; individual platforms vary by indication, configuration, and regulatory status. Competitor examples are illustrative and non-exhaustive.
How We Think About Our Position
DNAI sits at the intersection of data-driven machine learning and mechanistic simulation.
We use multi-omics and histopathology data to automatically parameterize physics-constrained dynamical models of tumor evolution, producing per-patient temporal trajectories under different treatment scenarios.
This combines the scalability of modern ML with the interpretability and constraint guarantees of mechanistic modeling — a hybrid approach we call neuro-symbolic oncology simulation.
Each prediction carries reliability metadata: calibrated uncertainty, out-of-distribution detection, per-cancer performance tiers, and structured abstention when evidence is insufficient.
The underlying methods are covered by 8 U.S. Provisional Patent Applications (filed Jan–Feb 2026).
Known Limitations
- •Drug sensitivity (beta) is estimated from survival endpoints, not direct drug-response data. Treatment ranking is validated; dose-response magnitudes are not.
- •External validation coverage at high-confidence tier is 22.2% (229 of 1,031 CPTAC patients). The system abstains on the remainder.
- •Performance varies by cancer type. 18 of 33 types meet reliability thresholds; 5 have insufficient training data.
- •Treatment rankings are probabilistic; point estimates show high variance under uncertainty quantification. Ranking is more reliable than individual predictions.
- •Some cancer types (e.g., BRCA) require histopathology input for accurate prediction. Omics-only performance is degraded.
Related Whitepapers
Interested in learning more?
Schedule a demo with our team.
For Research Use Only. DNAI is not a medical device and has not been cleared or approved by the FDA for clinical decision-making. Not validated for selecting therapy for individual patients. Metrics reflect Model V3.1 / VAE V5.10 snapshot as of February 2026; performance may vary by cancer type and data completeness. 8 U.S. Provisional Patent Applications filed.